Full Press Release Details
of AGM Clarification
Australia, September 30, 2020: Immuron Limited (ASX: IMC; NASDQ: IMRN), would like to clarify the time that the Company's
Annual General Meeting (AGM) will be held as disclosed on the Notice of 2020 AGM previously released.
| Date of Meeting: | Thursday, 29 th October 2020 |
| Time of Meeting ( Melbourne, Australia time ): | 4:30pm (Registration from 4:15pm) |
else being the same.
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally
delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel
and safe technology platform with one commercial asset generating revenue. In Australia, Travelan is a listed
medicine on the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers'
Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licenced natural
health product (NPN 80046016) and is indicated to reduce the risk of Travellers' Diarrhea. In the U.S., Travelan is
sold as a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration
more information visit: http://www.immuron.com